Results to be presented at the SPIE Medical Imaging conference in
Houston, TX, USA
SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News:
Median Technologies, the industry-leading Imaging Phenomics Company®
(Paris:ALMDT) announced today results of a deep learning study for
enhanced prostate segmentation. With more accurate segmentation, new
therapeutic decision-making tools can help advance precision medicine.
Study results will be presented at the SPIE Medical Imaging conference
in Houston, TX, USA on February 14.
The study, “Assessing the relevance of multi-planar MRI
acquisitions for prostate segmentation using deep learning techniques,”
relates to prostate cancer detection and presents a deep learning-based
method for prostate segmentation using magnetic resonance images
acquired in two imaging views. The results were compared to manual
tracings performed by medical image analysts and were evaluated by the
number of cancerous lesions within the segmentation. The study shows the
proposed method performs better than methods relying on a single imaging
view. This highlights the possibilities for design of fully automatic,
accurate, fast and reproducible prostate segmentation computer systems.
Deep learning, a field of artificial intelligence, enables computer
systems to improve analysis by using experience and data. It has very
promising applications in healthcare, particularly in the medical
imaging field to develop computer-aided systems for the management of
diseases such as cancer. A key step in developing computer-aided systems
for cancer detection is organ segmentation.
The study will be presented during the poster session, “Machine Learning
and Artificial Intelligence,” to be held on Wednesday 14 February, from
5:30p to 7:00p CST.
Please visit SPIE
Medical Imaging Conference, for more information on the conference.
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We leverage the power of Imaging Phenomics to provide insights
into novel therapies and treatment strategies. Our unique solutions,
MediScan® for Patient Care, iSee® for image
management in clinical trials and iBiopsy® for imaging
phenotyping, together with our global team of experts, are advancing the
development of new drugs and diagnostic tools to monitor disease and
assess response to therapy. Median Technologies supports
biopharmaceutical sponsors and healthcare professionals around the world
to quickly and precisely bring new treatments to patients in need, with
an eye on reducing overall care costs. This is how we are helping to
create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary
in Boston, Median has received the label “Innovative company” by the BPI
and is listed on Euronext Growth market (ISIN: FR0011049824, ticker:
ALMDT). The company is eligible for the PEA-PME SME equity savings plan
setup and has received the label Pass French Tech Promotion 2017-2018.
Median Technologies has been awarded the 2017 Tech 40 Label, has joined
the EnterNext Tech 40 Index and is a winner of the Deloitte Technology
Fast 500™ 2017 EMEA program. Median is a member of the Bpifrance
Excellence Network. For more information: www.mediantechnologies.com
VP, Head of
Investor and Media Relations
+1 312 282 3923
– ALIZE RP
Caroline Carmagnol /Wendy Rigal
+ 33 1 44 54 36
+33 1 56 88 11 11